This Viewpoint discusses the challenges clinicians face individualizing decisions for patients about the benefits and risks of using aspirin for primary prevention of cardiovascular disease.
This study estimates the cost-effectiveness of adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD).
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on screening for lipid disorders in children and adolescents summarizes published evidence about the effectiveness of routine screening, accuracy of screening tests and strategies, and potential screening harms.
This Viewpoint discusses the need for examination of long-term patterns across a broad range of risk factors in predicting patients’ lifetime risk of atherosclerotic cardiovascular disease.
This randomized trial tested the effects of daily testosterone vs placebo gel administered for 3 years on progression of subclinical atherosclerosis in men aged 60 years or older with low or low-normal testosterone levels.
This study compares the cost-effectiveness of using various 10-year atherosclerotic cardiovascular disease risk thresholds for initiating statin therapy.
This retrospective pooled analysis of 8 clinical trials reports that obstructive non–infarct-related artery disease was common among patients presenting with ST-elevation myocardial infarction (STEMI).
This randomized clinical trial of 4524 patients undergoing transfemoral coronary angiography reports that vascular closure devices were noninferior to manual compression in terms of vascular access-site complications and reduced time to hemostasis.
Muntner and coauthors report on validation of the atherosclerotic CVD pooled cohort risk equations. In an accompanying Editorial, Krumholz provides persective on the new cholesterol and blood pressure guidelines.
Kavousi and coauthors compared population-wide implications of the ACC/AHA, Adult Treatment Panel III, and European Society of Cardiology guidelines for cardiovascular disease (CVD) prevention in 4854 Dutch Rotterdam Study participants. Krumholz comments in an editorial.
Allen and coauthors analyzed data from the prospective CARDIA cohort to identify common blood pressure (BP) trajectories throughout early adulthood and to determine their association with presence of subclinical atherosclerosis during middle age. Sarafidis and Bakris comment in an editorial.
Nicholls and coauthors report the results from the randomized clinical Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS). In an accompanying Editorial, Tardiff and Grégoire discuss renin-angiotensin system inhibition and secondary cardiovascular prevention.